Last updated: February 20, 2026
What is NDC 00096-0736?
NDC 00096-0736 corresponds to Indomethacin capsules 50 mg, a nonsteroidal anti-inflammatory drug (NSAID) indicated for pain, inflammation, and acute gouty arthritis. It is marketed primarily by Mallinckrodt Pharmaceuticals under the brand name Indocin, among others.
Market Size and Demand Drivers
Therapeutic Use and Market Demand
- Utilized mainly for gout, osteoarthritis, and rheumatoid arthritis.
- Prescriptions in the U.S. totaled approximately 500,000 units in 2022 (IQVIA, 2022).
- The volume remains stable, with slight annual growth driven by aging populations and increased arthritis diagnoses.
Competitive Landscape
- Other NSAIDs: Diclofenac, Naproxen, Ibuprofen, Celecoxib.
- Biosimilar and generic entries: Multiple generics available lowering barriers.
- Market share distribution indicates approximately 60% of sales are generic versions.
Regulatory Environment
- No recent FDA drug recalls or safety alerts specific to Indomethacin.
- Patent expiry: The original patent expired in the late 1990s, leading to widespread generics.
Reimbursement and Coverage
- Broad insurance coverage in the U.S.
- Medicare and Medicaid include coverage with minimal restrictions.
- Price sensitivity influences prescribing patterns, especially with generics.
Price Analysis
Current Pricing (2023)
| Product Type |
Price Range per Capsule |
Notes |
| Brand Name (Indocin) |
$3.50 - $5.00 |
Limited quantities, higher margins |
| Brand Equivalent (Indomethacin branded) |
$3.50 - $4.80 |
Exact same formulation |
| Generic (multiple manufacturers) |
$0.30 - $0.80 |
Most commonly prescribed, lowest price |
Price Trends
- Generic price per capsule has decreased by approximately 25% over the past three years.
- Brand names maintain a premium, with prices about 6x higher than generics.
- Rebates and discounts often reduce effective patient costs.
Wholesale and Retail Margins
- Wholesale acquisition cost (WAC): $0.20 - $0.50 per capsule.
- Average retail price: $0.30 - $0.80 per capsule, depending on pharmacy contracts.
- Patient out-of-pocket costs vary, often subsidized by insurance.
Projected Pricing Dynamics (Next 2-3 Years)
| Scenario |
Price Range per Capsule |
Key Factors |
| Stable market |
$0.25 - $0.80 |
Ongoing generic competition maintains low prices |
| Slight price decrease |
$0.20 - $0.70 |
Increased biosimilar and generic entry, cost pressures persist |
| Price increase potential |
$0.40 - $1.00 (brand) |
Possible supply chain disruptions or regulatory changes |
Future Market and Price Projection
- The generic segment will remain dominant, exerting downward pressure on prices.
- Brand-name products may maintain higher prices if supply constraints or patent disputes arise.
- The market is unlikely to see significant price inflation due to high generic competition.
Key Considerations
- Patent expiration: No active patent protections, facilitating entry of generics.
- Healthcare policy: Growing emphasis on cost containing measures favors lower-cost generics.
- Supply chain: Supply disruptions could temporarily affect prices but unlikely to impact long-term trends substantially.
Final Summary
NDC 00096-0736, Indomethacin capsules 50 mg, operates within a mature, saturated market with extensive generic competition. Prices have trended downward due to generics, with current retail prices averaging less than $1 per capsule. Future prices are expected to stay low, barring unforeseen supply or regulatory events.
Key Takeaways
- Market demand is stable, driven by arthritis and gout treatments.
- The competition from generics suppresses prices; retail cost per capsule averages below $1.
- No patent protections are in place, enabling intense price competition.
- Price projections indicate minimal increase, with continued downward pressure.
- Overall, the market remains mature, with margins primarily sustained by brand premiums.
FAQs
Q1: How does generic competition impact pricing for indomethacin?
It drives prices downward; generics account for most sales and are priced at a fraction of brand-name costs.
Q2: Are there any regulatory risks influencing the market?
No significant regulatory risks currently. Patent expiry and safety records favor sustained generic entry.
Q3: Can price increases occur despite competition?
Only if supply disruptions or regulatory actions limit generic availability.
Q4: Is there potential for market growth?
Limited; demand is stable, based on existing indications, with no major label extensions expected.
Q5: How do insurance formularies influence retail prices?
Insurance coverage reduces patient out-of-pocket costs, often favoring generic purchases.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. (2022). Drug Approvals and Labeling.
[3] Medicare.gov. (2023). Drug Coverage and Reimbursement Data.
